JP2017515871A - 安定性を向上させたロチゴチン含有経皮吸収製剤 - Google Patents

安定性を向上させたロチゴチン含有経皮吸収製剤 Download PDF

Info

Publication number: JP2017515871A
Authority: JP; Japan
Prior art keywords: rotigotine; antioxidant; present; drug; weight ratio
Prior art date: 2014-05-21
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

JP2016568519A

Other languages

English (en)

Japanese (ja)

Inventor

ヨウン、ウォンノ

パク、ヨ−ジン

キム、フン−テク

Original Assignee

エスケーケミカルスカンパニーリミテッド

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-05-21

Filing date

2015-05-20

Publication date

2017-06-15

2015-05-20 Application filed by エスケーケミカルスカンパニーリミテッド, エスケーケミカルスカンパニーリミテッド filed Critical エスケーケミカルスカンパニーリミテッド

2017-06-15 Publication of JP2017515871A publication Critical patent/JP2017515871A/ja

Status Pending legal-status Critical Current

Links

KFQYTPMOWPVWEJ-INIZCTEOSA-N rotigotine Chemical compound CCCN([C@@H]1CC2=CC=CC(O)=C2CC1)CCC1=CC=CS1 KFQYTPMOWPVWEJ-INIZCTEOSA-N 0.000 title claims abstract description 118
229960003179 rotigotine Drugs 0.000 title claims abstract description 118
238000002360 preparation method Methods 0.000 title claims abstract description 49
238000010521 absorption reaction Methods 0.000 title description 14
239000003963 antioxidant agent Substances 0.000 claims abstract description 97
230000003078 antioxidant effect Effects 0.000 claims abstract description 95
229940079593 drug Drugs 0.000 claims abstract description 33
239000003814 drug Substances 0.000 claims abstract description 33
239000004820 Pressure-sensitive adhesive Substances 0.000 claims abstract description 31
238000000034 method Methods 0.000 claims abstract description 28
239000010410 layer Substances 0.000 claims abstract description 22
238000004519 manufacturing process Methods 0.000 claims abstract description 20
230000001225 therapeutic effect Effects 0.000 claims abstract description 19
238000002425 crystallisation Methods 0.000 claims abstract description 14
230000008025 crystallization Effects 0.000 claims abstract description 12
235000006708 antioxidants Nutrition 0.000 claims description 95
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 58
229960005070 ascorbic acid Drugs 0.000 claims description 29
235000010323 ascorbic acid Nutrition 0.000 claims description 26
239000011668 ascorbic acid Substances 0.000 claims description 26
WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 claims description 24
238000002156 mixing Methods 0.000 claims description 17
ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 claims description 16
239000000853 adhesive Substances 0.000 claims description 15
230000001070 adhesive effect Effects 0.000 claims description 15
239000011786 L-ascorbyl-6-palmitate Substances 0.000 claims description 14
QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 claims description 11
235000010385 ascorbyl palmitate Nutrition 0.000 claims description 11
239000000126 substance Substances 0.000 claims description 11
PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 claims description 10
NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 claims description 8
GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 8
235000010388 propyl gallate Nutrition 0.000 claims description 8
239000000473 propyl gallate Substances 0.000 claims description 8
229940075579 propyl gallate Drugs 0.000 claims description 8
GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims description 8
CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 claims description 7
239000000203 mixture Substances 0.000 claims description 7
150000002148 esters Chemical class 0.000 claims description 6
235000010384 tocopherol Nutrition 0.000 claims description 6
239000011732 tocopherol Substances 0.000 claims description 6
229960001295 tocopherol Drugs 0.000 claims description 6
229930003799 tocopherol Natural products 0.000 claims description 6
229920001971 elastomer Polymers 0.000 claims description 3
239000005060 rubber Substances 0.000 claims description 3
DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 claims description 2
239000005038 ethylene vinyl acetate Substances 0.000 claims description 2
229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 claims description 2
239000013464 silicone adhesive Substances 0.000 claims description 2
239000003522 acrylic cement Substances 0.000 claims 1
239000012535 impurity Substances 0.000 abstract description 28
239000013078 crystal Substances 0.000 abstract description 26
238000003860 storage Methods 0.000 abstract description 17
238000001556 precipitation Methods 0.000 abstract description 13
239000004480 active ingredient Substances 0.000 abstract description 9
239000008186 active pharmaceutical agent Substances 0.000 description 14
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
239000003795 chemical substances by application Substances 0.000 description 7
230000000694 effects Effects 0.000 description 7
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 5
230000000052 comparative effect Effects 0.000 description 5
235000014113 dietary fatty acids Nutrition 0.000 description 5
239000002552 dosage form Substances 0.000 description 5
229930195729 fatty acid Natural products 0.000 description 5
239000000194 fatty acid Substances 0.000 description 5
-1 fatty acid esters Chemical class 0.000 description 5
230000001965 increasing effect Effects 0.000 description 5
230000007774 longterm Effects 0.000 description 5
229910052710 silicon Inorganic materials 0.000 description 5
239000010703 silicon Substances 0.000 description 5
LDXJRKWFNNFDSA-UHFFFAOYSA-N 2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]ethanone Chemical compound C1CN(CC2=NNN=C21)CC(=O)N3CCN(CC3)C4=CN=C(N=C4)NCC5=CC(=CC=C5)OC(F)(F)F LDXJRKWFNNFDSA-UHFFFAOYSA-N 0.000 description 4
SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 4
AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 4
208000005793 Restless legs syndrome Diseases 0.000 description 4
239000011248 coating agent Substances 0.000 description 4
238000000576 coating method Methods 0.000 description 4
238000002474 experimental method Methods 0.000 description 4
230000003647 oxidation Effects 0.000 description 4
238000007254 oxidation reaction Methods 0.000 description 4
239000003381 stabilizer Substances 0.000 description 4
OHVLMTFVQDZYHP-UHFFFAOYSA-N 1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-2-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]ethanone Chemical compound N1N=NC=2CN(CCC=21)C(CN1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)=O OHVLMTFVQDZYHP-UHFFFAOYSA-N 0.000 description 3
235000000072 L-ascorbyl-6-palmitate Nutrition 0.000 description 3
208000018737 Parkinson disease Diseases 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
239000012790 adhesive layer Substances 0.000 description 3
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 3
229910052782 aluminium Inorganic materials 0.000 description 3
238000011156 evaluation Methods 0.000 description 3
150000004665 fatty acids Chemical class 0.000 description 3
IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 3
239000003112 inhibitor Substances 0.000 description 3
239000002674 ointment Substances 0.000 description 3
229920000139 polyethylene terephthalate Polymers 0.000 description 3
239000005020 polyethylene terephthalate Substances 0.000 description 3
SPSPIUSUWPLVKD-UHFFFAOYSA-N 2,3-dibutyl-6-methylphenol Chemical compound CCCCC1=CC=C(C)C(O)=C1CCCC SPSPIUSUWPLVKD-UHFFFAOYSA-N 0.000 description 2
KFQYTPMOWPVWEJ-UHFFFAOYSA-N 6-{propyl[2-(thiophen-2-yl)ethyl]amino}-5,6,7,8-tetrahydronaphthalen-1-ol Chemical compound C1CC2=C(O)C=CC=C2CC1N(CCC)CCC1=CC=CS1 KFQYTPMOWPVWEJ-UHFFFAOYSA-N 0.000 description 2
239000011627 DL-alpha-tocopherol Substances 0.000 description 2
235000001815 DL-alpha-tocopherol Nutrition 0.000 description 2
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
229920002367 Polyisobutene Polymers 0.000 description 2
239000002174 Styrene-butadiene Substances 0.000 description 2
230000002745 absorbent Effects 0.000 description 2
239000002250 absorbent Substances 0.000 description 2
239000013543 active substance Substances 0.000 description 2
239000000654 additive Substances 0.000 description 2
239000000010 aprotic solvent Substances 0.000 description 2
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
MTAZNLWOLGHBHU-UHFFFAOYSA-N butadiene-styrene rubber Chemical compound C=CC=C.C=CC1=CC=CC=C1 MTAZNLWOLGHBHU-UHFFFAOYSA-N 0.000 description 2
235000010354 butylated hydroxytoluene Nutrition 0.000 description 2
VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
239000003623 enhancer Substances 0.000 description 2
150000002191 fatty alcohols Chemical class 0.000 description 2
238000009472 formulation Methods 0.000 description 2
239000012456 homogeneous solution Substances 0.000 description 2
239000007788 liquid Substances 0.000 description 2
239000003960 organic solvent Substances 0.000 description 2
239000003961 penetration enhancing agent Substances 0.000 description 2
238000006303 photolysis reaction Methods 0.000 description 2
230000015843 photosynthesis, light reaction Effects 0.000 description 2
229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
239000001267 polyvinylpyrrolidone Substances 0.000 description 2
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
239000000047 product Substances 0.000 description 2
HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 2
235000010262 sodium metabisulphite Nutrition 0.000 description 2
GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
239000002904 solvent Substances 0.000 description 2
229920006132 styrene block copolymer Polymers 0.000 description 2
239000011115 styrene butadiene Substances 0.000 description 2
229920003048 styrene butadiene rubber Polymers 0.000 description 2
239000000758 substrate Substances 0.000 description 2
229960000984 tocofersolan Drugs 0.000 description 2
KZEVSDGEBAJOTK-UHFFFAOYSA-N 1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-2-[5-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]-1,3,4-oxadiazol-2-yl]ethanone Chemical compound N1N=NC=2CN(CCC=21)C(CC=1OC(=NN=1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)=O KZEVSDGEBAJOTK-UHFFFAOYSA-N 0.000 description 1
HMUNWXXNJPVALC-UHFFFAOYSA-N 1-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C(CN1CC2=C(CC1)NN=N2)=O HMUNWXXNJPVALC-UHFFFAOYSA-N 0.000 description 1
KGRVJHAUYBGFFP-UHFFFAOYSA-N 2,2'-Methylenebis(4-methyl-6-tert-butylphenol) Chemical compound CC(C)(C)C1=CC(C)=CC(CC=2C(=C(C=C(C)C=2)C(C)(C)C)O)=C1O KGRVJHAUYBGFFP-UHFFFAOYSA-N 0.000 description 1
VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
LCZVSXRMYJUNFX-UHFFFAOYSA-N 2-[2-(2-hydroxypropoxy)propoxy]propan-1-ol Chemical compound CC(O)COC(C)COC(C)CO LCZVSXRMYJUNFX-UHFFFAOYSA-N 0.000 description 1
SXAMGRAIZSSWIH-UHFFFAOYSA-N 2-[3-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-1,2,4-oxadiazol-5-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1=NOC(=N1)CC(=O)N1CC2=C(CC1)NN=N2 SXAMGRAIZSSWIH-UHFFFAOYSA-N 0.000 description 1
WZFUQSJFWNHZHM-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC(=O)N1CC2=C(CC1)NN=N2 WZFUQSJFWNHZHM-UHFFFAOYSA-N 0.000 description 1
JQMFQLVAJGZSQS-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-N-(2-oxo-3H-1,3-benzoxazol-6-yl)acetamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC(=O)NC1=CC2=C(NC(O2)=O)C=C1 JQMFQLVAJGZSQS-UHFFFAOYSA-N 0.000 description 1
ZRPAUEVGEGEPFQ-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]pyrazol-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C=1C=NN(C=1)CC(=O)N1CC2=C(CC1)NN=N2 ZRPAUEVGEGEPFQ-UHFFFAOYSA-N 0.000 description 1
VXZBYIWNGKSFOJ-UHFFFAOYSA-N 2-[4-[5-(2,3-dihydro-1H-inden-2-ylamino)pyrazin-2-yl]pyrazol-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC=1N=CC(=NC=1)C=1C=NN(C=1)CC(=O)N1CC2=C(CC1)NN=N2 VXZBYIWNGKSFOJ-UHFFFAOYSA-N 0.000 description 1
YJLUBHOZZTYQIP-UHFFFAOYSA-N 2-[5-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-1,3,4-oxadiazol-2-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1=NN=C(O1)CC(=O)N1CC2=C(CC1)NN=N2 YJLUBHOZZTYQIP-UHFFFAOYSA-N 0.000 description 1
ROGIWVXWXZRRMZ-UHFFFAOYSA-N 2-methylbuta-1,3-diene;styrene Chemical compound CC(=C)C=C.C=CC1=CC=CC=C1 ROGIWVXWXZRRMZ-UHFFFAOYSA-N 0.000 description 1
VSKJLJHPAFKHBX-UHFFFAOYSA-N 2-methylbuta-1,3-diene;styrene Chemical compound CC(=C)C=C.C=CC1=CC=CC=C1.C=CC1=CC=CC=C1 VSKJLJHPAFKHBX-UHFFFAOYSA-N 0.000 description 1
YLZOPXRUQYQQID-UHFFFAOYSA-N 3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]propan-1-one Chemical compound N1N=NC=2CN(CCC=21)CCC(=O)N1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F YLZOPXRUQYQQID-UHFFFAOYSA-N 0.000 description 1
CONKBQPVFMXDOV-QHCPKHFHSA-N 6-[(5S)-5-[[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]methyl]-2-oxo-1,3-oxazolidin-3-yl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C[C@H]1CN(C(O1)=O)C1=CC2=C(NC(O2)=O)C=C1 CONKBQPVFMXDOV-QHCPKHFHSA-N 0.000 description 1
AWFDCTXCTHGORH-HGHGUNKESA-N 6-[4-[(6ar,9r,10ar)-5-bromo-7-methyl-6,6a,8,9,10,10a-hexahydro-4h-indolo[4,3-fg]quinoline-9-carbonyl]piperazin-1-yl]-1-methylpyridin-2-one Chemical compound O=C([C@H]1CN([C@H]2[C@@H](C=3C=CC=C4NC(Br)=C(C=34)C2)C1)C)N(CC1)CCN1C1=CC=CC(=O)N1C AWFDCTXCTHGORH-HGHGUNKESA-N 0.000 description 1
239000005711 Benzoic acid Substances 0.000 description 1
229920002799 BoPET Polymers 0.000 description 1
ONVFBJYWRFDKDU-UHFFFAOYSA-N C=CC(C)=C.C=CC1=CC=CC=C1.C=CC(C)=C.C=CC1=CC=CC=C1 Chemical compound C=CC(C)=C.C=CC1=CC=CC=C1.C=CC(C)=C.C=CC1=CC=CC=C1 ONVFBJYWRFDKDU-UHFFFAOYSA-N 0.000 description 1
206010012289 Dementia Diseases 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
206010020751 Hypersensitivity Diseases 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
206010059516 Skin toxicity Diseases 0.000 description 1
DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
AVRWEULSKHQETA-UHFFFAOYSA-N Thiophene-2 Chemical compound S1C=2CCCCCC=2C(C(=O)OC)=C1NC(=O)C1=C(F)C(F)=C(F)C(F)=C1F AVRWEULSKHQETA-UHFFFAOYSA-N 0.000 description 1
NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
238000001467 acupuncture Methods 0.000 description 1
230000000996 additive effect Effects 0.000 description 1
230000003113 alkalizing effect Effects 0.000 description 1
208000030961 allergic reaction Diseases 0.000 description 1
235000010233 benzoic acid Nutrition 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
229920001400 block copolymer Polymers 0.000 description 1
FACXGONDLDSNOE-UHFFFAOYSA-N buta-1,3-diene;styrene Chemical compound C=CC=C.C=CC1=CC=CC=C1.C=CC1=CC=CC=C1 FACXGONDLDSNOE-UHFFFAOYSA-N 0.000 description 1
BUILWQRVQTVUTH-UHFFFAOYSA-N butanoic acid;2-methoxyphenol Chemical compound CCCC(O)=O.COC1=CC=CC=C1O BUILWQRVQTVUTH-UHFFFAOYSA-N 0.000 description 1
LNHFOFJKSJHYGR-UHFFFAOYSA-N butanoic acid;phenylmethanol Chemical compound CCCC(O)=O.OCC1=CC=CC=C1 LNHFOFJKSJHYGR-UHFFFAOYSA-N 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
229960001714 calcium phosphate Drugs 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000001934 delay Effects 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
230000008021 deposition Effects 0.000 description 1
238000003795 desorption Methods 0.000 description 1
229940028356 diethylene glycol monobutyl ether Drugs 0.000 description 1
SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
238000009826 distribution Methods 0.000 description 1
229960003638 dopamine Drugs 0.000 description 1
229940052760 dopamine agonists Drugs 0.000 description 1
239000003136 dopamine receptor stimulating agent Substances 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
238000012377 drug delivery Methods 0.000 description 1
230000000857 drug effect Effects 0.000 description 1
125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 description 1
239000008103 glucose Substances 0.000 description 1
230000036541 health Effects 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
230000006872 improvement Effects 0.000 description 1
238000004811 liquid chromatography Methods 0.000 description 1
239000000463 material Substances 0.000 description 1
239000004745 nonwoven fabric Substances 0.000 description 1
150000007523 nucleic acids Chemical class 0.000 description 1
102000039446 nucleic acids Human genes 0.000 description 1
108020004707 nucleic acids Proteins 0.000 description 1
239000003921 oil Substances 0.000 description 1
JCGNDDUYTRNOFT-UHFFFAOYSA-N oxolane-2,4-dione Chemical compound O=C1COC(=O)C1 JCGNDDUYTRNOFT-UHFFFAOYSA-N 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
230000035699 permeability Effects 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
150000003904 phospholipids Chemical class 0.000 description 1
229920000728 polyester Polymers 0.000 description 1
229920006267 polyester film Polymers 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
229920001451 polypropylene glycol Polymers 0.000 description 1
229920002635 polyurethane Polymers 0.000 description 1
239000004814 polyurethane Substances 0.000 description 1
229920000915 polyvinyl chloride Polymers 0.000 description 1
239000004800 polyvinyl chloride Substances 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
230000001376 precipitating effect Effects 0.000 description 1
230000002265 prevention Effects 0.000 description 1
HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
150000004040 pyrrolidinones Chemical class 0.000 description 1
230000009257 reactivity Effects 0.000 description 1
230000009467 reduction Effects 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
238000000926 separation method Methods 0.000 description 1
230000037384 skin absorption Effects 0.000 description 1
231100000274 skin absorption Toxicity 0.000 description 1
231100000438 skin toxicity Toxicity 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
229940083542 sodium Drugs 0.000 description 1
235000015424 sodium Nutrition 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
229940001584 sodium metabisulfite Drugs 0.000 description 1
235000010265 sodium sulphite Nutrition 0.000 description 1
230000000087 stabilizing effect Effects 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
229920000468 styrene butadiene styrene block copolymer Polymers 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
239000000341 volatile oil Substances 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Dermatology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Oil, Petroleum & Natural Gas (AREA)
Psychology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

JP2016568519A 2014-05-21 2015-05-20 安定性を向上させたロチゴチン含有経皮吸収製剤 Pending JP2017515871A (ja)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
KR1020140061193A KR102364378B1 (ko)	2014-05-21	2014-05-21	안정성을 향상시킨 로티고틴 함유 경피흡수제제
KR10-2014-0061193		2014-05-21
PCT/KR2015/005045 WO2015178679A1 (ko)	2014-05-21	2015-05-20	안정성을 향상시킨 로티고틴 함유 경피흡수제제

Publications (1)

Publication Number	Publication Date
JP2017515871A true JP2017515871A (ja)	2017-06-15

Family

ID=54554275

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP2016568519A Pending JP2017515871A (ja)	2014-05-21	2015-05-20	安定性を向上させたロチゴチン含有経皮吸収製剤

Country Status (6)

Country	Link
US (1)	US9877948B2 (de)
EP (1)	EP3146980A4 (de)
JP (1)	JP2017515871A (de)
KR (1)	KR102364378B1 (de)
CN (1)	CN106604748A (de)
WO (1)	WO2015178679A1 (de)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2019124261A1 (ja)	2017-12-19	2019-06-27	久光製薬株式会社	ロチゴチン含有貼付剤
WO2020166298A1 (ja)	2019-02-15	2020-08-20	久光製薬株式会社	ロチゴチン安定化方法
WO2022172915A1 (ja)	2021-02-10	2022-08-18	コスメディ製薬株式会社	酸化防止剤含有経皮吸収製剤
JP7322324B1 (ja) *	2022-02-21	2023-08-07	久光製薬株式会社	ロチゴチン含有貼付剤
WO2023157865A1 (ja)	2022-02-21	2023-08-24	久光製薬株式会社	ロチゴチン含有貼付剤
JPWO2024116965A1 (de) *	2022-12-01	2024-06-06

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP7075937B2 (ja) *	2016-11-09	2022-05-26	キアゲンサイエンシーズ，エルエルシー	Ｓｅｑｕｅｎｃｉｎｇ－Ｂｙ－Ｓｙｎｔｈｅｓｉｓ法におけるイメージング試薬としての光防護性混合物
CN108451934B (zh) *	2017-07-19	2020-11-10	北京泰德制药股份有限公司	一种含有罗替高汀的透皮贴剂及其制备方法
CN120417892A (zh) *	2022-12-26	2025-08-01	丸仁制药株式会社	透皮吸收制剂及其制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AUPN814496A0 (en)	1996-02-19	1996-03-14	Monash University	Dermal penetration enhancer
DE19814084B4 (de)	1998-03-30	2005-12-22	Lts Lohmann Therapie-Systeme Ag	D2-Agonist enthaltendes transdermales therapeutisches System zur Behandlung des Parkinson-Syndroms und Verfahren zu seiner Herstellung
EP1256339B1 (de) *	2001-05-08	2003-10-15	Schwarz Pharma Ag	Transdermales therapeutisches System für die Erzielung hoher Plasmaspiegel von Rotigotin in der Therapie von Morbus Parkinson
EP1386605A1 (de) *	2002-07-30	2004-02-04	Schwarz Pharma Ag	Verbessertes transdermales System für die Verabreichung von Rotigotin
US8246979B2 (en)	2002-07-30	2012-08-21	Ucb Pharma Gmbh	Transdermal delivery system for the administration of rotigotine
DE10234673B4 (de) *	2002-07-30	2007-08-16	Schwarz Pharma Ag	Heißschmelz-TTS zur Verabreichung von Rotigotin und Verfahren zu seiner Herstellung sowie Verwendung von Rotigotin bei der Herstellung eines TTS im Heißschmelzverfahren
US8211462B2 (en)	2002-07-30	2012-07-03	Ucb Pharma Gmbh	Hot-melt TTS for administering rotigotine
DE10261696A1 (de) *	2002-12-30	2004-07-15	Schwarz Pharma Ag	Vorrichtung zur transdermalen Verabreichung von Rotigotin-Base
CN101147739B (zh) *	2007-07-06	2010-12-08	北京康倍得医药技术开发有限公司	含罗替戈汀的组合物及其制药用途以及含该组合物的透皮贴剂
AU2009302853B2 (en) *	2008-10-06	2014-09-11	Mylan Technologies, Inc.	Amorphous rotigotine transdermal system
KR101325104B1 (ko) *	2009-09-16	2013-11-07	주식회사 삼양바이오팜	경피 투여 제형 및 그 제조 방법
LT3257504T (lt)	2009-12-22	2024-08-26	UCB Biopharma SRL	Polivinilpirolidonas, skirtas nekristalinės formos kietos rotigotino dispersijos stabilizavimui
WO2013075823A1 (en) *	2011-11-22	2013-05-30	Alfred E. Tiefenbacher (Gmbh & Co. Kg)	Transdermal therapeutic system comprising rotigotine and crystallization inhibitor
EP2870963A4 (de) *	2012-07-06	2016-03-09	Sk Chemicals Co Ltd	Zubereitung zur perkutanen absorption mit rotigotin

2014
- 2014-05-21 KR KR1020140061193A patent/KR102364378B1/ko active Active
2015
- 2015-05-20 EP EP15795996.6A patent/EP3146980A4/de not_active Withdrawn
- 2015-05-20 CN CN201580040875.7A patent/CN106604748A/zh active Pending
- 2015-05-20 WO PCT/KR2015/005045 patent/WO2015178679A1/ko not_active Ceased
- 2015-05-20 JP JP2016568519A patent/JP2017515871A/ja active Pending
2016
- 2016-11-17 US US15/354,716 patent/US9877948B2/en not_active Expired - Fee Related

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2019124261A1 (ja)	2017-12-19	2019-06-27	久光製薬株式会社	ロチゴチン含有貼付剤
KR20200074186A (ko)	2017-12-19	2020-06-24	히사미쓰 세이야꾸 가부시키가이샤	로티고틴 함유 첩부제
US11607394B2 (en)	2017-12-19	2023-03-21	Hisamitsu Pharmaceutical Co., Inc.	Rotigotine-containing patch
WO2020166298A1 (ja)	2019-02-15	2020-08-20	久光製薬株式会社	ロチゴチン安定化方法
KR20210104101A (ko)	2019-02-15	2021-08-24	히사미쓰 세이야꾸 가부시키가이샤	로티고틴 안정화 방법
WO2022172915A1 (ja)	2021-02-10	2022-08-18	コスメディ製薬株式会社	酸化防止剤含有経皮吸収製剤
JP7322324B1 (ja) *	2022-02-21	2023-08-07	久光製薬株式会社	ロチゴチン含有貼付剤
WO2023157865A1 (ja)	2022-02-21	2023-08-24	久光製薬株式会社	ロチゴチン含有貼付剤
KR20240141338A (ko)	2022-02-21	2024-09-26	히사미쓰 세이야꾸 가부시키가이샤	로티고틴 함유 첩부제
JPWO2024116965A1 (de) *	2022-12-01	2024-06-06
WO2024116965A1 (ja)	2022-12-01	2024-06-06	久光製薬株式会社	ロチゴチン含有貼付剤及びロチゴチン安定性向上方法
KR20250112885A (ko)	2022-12-01	2025-07-24	히사미쓰 세이야꾸 가부시키가이샤	로티고틴 함유 첩부제 및 로티고틴 안정성 향상 방법
JP7716603B2 (ja)	2022-12-01	2025-07-31	久光製薬株式会社	ロチゴチン含有貼付剤及びロチゴチン安定性向上方法
EP4628076A1 (de)	2022-12-01	2025-10-08	Hisamitsu Pharmaceutical Co., Inc.	Rotigotinhaltiges pflaster und verfahren zur verbesserung der stabilität von rotigotin

Also Published As

Publication number	Publication date
CN106604748A (zh)	2017-04-26
WO2015178679A1 (ko)	2015-11-26
EP3146980A1 (de)	2017-03-29
US9877948B2 (en)	2018-01-30
EP3146980A4 (de)	2017-10-25
KR102364378B1 (ko)	2022-02-16
KR20150134176A (ko)	2015-12-01
US20170128413A1 (en)	2017-05-11

Publication	Publication Date	Title
JP2017515871A (ja)	2017-06-15	安定性を向上させたロチゴチン含有経皮吸収製剤
JP5936544B2 (ja)	2016-06-22	安定なラサギリン組成物
CN103338771B (zh)	2016-04-06	贴剂
CN103347522B (zh)	2015-09-02	透皮贴剂
CN110022864B (zh)	2023-06-06	用于治疗睡眠障碍的经皮吸收制剂
JP2015522013A (ja)	2015-08-03	ロチゴチン含有経皮吸収製剤
CN111542311B (zh)	2023-07-14	用于治疗痴呆症的含有多奈哌齐的透皮吸收制剂
JP6180520B2 (ja)	2017-08-16	ロチゴチンを含有した経皮吸収製剤（Ｔｒａｎｓｄｅｒｍａｌｃｏｍｐｏｓｉｔｉｏｎｃｏｍｐｒｉｓｉｎｇｒｏｔｉｇｏｔｉｎｅ）
CN102076340B (zh)	2013-01-23	含芬太尼或其盐的经皮吸收型贴剂
ES2971461T3 (es)	2024-06-05	Parche que contiene rupatadina
CA2800716C (en)	2019-11-05	Piroxicam-containing matrix patches and methods for the topical treatment of acute and chronic pain and inflammation therewith
KR101686987B1 (ko)	2016-12-15	로티고틴과 지방산 및 스티렌 점착제를 함유한 경피치료시스템
JP2020203839A (ja)	2020-12-24	経皮吸収型製剤の製造方法
WO2019160067A1 (ja)	2019-08-22	非水系貼付剤